Inhibitor Therapeutics (INTI) 10-Q 12 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	12-May-14
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Entity Registrant Name	'HedgePath Pharmaceuticals, Inc.	'
Entity Central Index Key	'0001042418	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	18,888,971

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$456	$217
Deferred stock issuance costs	10,000	10,000
Total current assets	10,456	10,217
Total assets	10,456	10,217
Current liabilities:	'	'
Accounts payable	355,097	287,072
Notes payable	77,701	68,428
Accrued interest	2,208	1,923
Other liabilities	62,900	52,500
Due to related party	474,874	366,130
Total current liabilities	972,780	776,053
Commitments and contingencies (note 4)	'	'
Stockholders' deficit:	'	'
Preferred stock value	'	'
Common Stock, $0.0001 par value; 340,000,000 shares authorized; 18,888,971 shares issued and outstanding.	1,889	1,889
Additional paid-in capital	27,479,913	27,479,913
Accumulated deficit	-28,444,143	-28,247,655
Total stockholders' deficit	-962,324	-765,836
Total liabilities and stockholders' deficit	10,456	10,217
Series A Preferred Stock [Member]	'	'
Stockholders' deficit:	'	'
Preferred stock value	$17	$17

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	9,500,000	9,500,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	340,000,000	340,000,000
Common stock, shares issued	18,888,971	18,888,971
Common stock, shares outstanding	18,888,971	18,888,971
Series A Preferred Stock [Member]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued	170,001	170,001
Preferred stock, shares outstanding	170,001	170,001

CONDENSED_STATEMENTS_OF_OPERAT

CONDENSED STATEMENTS OF OPERATIONS (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Revenues:	'	'
Total revenues:	'	'
Expenses:	'	'
Research and development	25,325	'
General and administrative	161,605	90,545
Total expenses:	186,930	90,545
Loss from operations	-186,930	-90,545
Interest expense	-9,558	'
Other income	'	30,000
Net loss	($196,488)	($60,545)
Basic and diluted loss per share	($0.01)	'
Weighted average common stock shares outstanding	18,888,971	15,560,504

CONDENSED_STATEMENT_OF_STOCKHO

CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT (Unaudited) (USD $)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Series A Preferred Stock [Member]
Beginning balance at Dec. 31, 2013	'	'	'	'	$17
Beginning balance at Dec. 31, 2013	-765,836	1,889	27,479,913	-28,247,655	'
Beginning balance, shares at Dec. 31, 2013	0	'	'	'	170,001
Beginning balance, shares at Dec. 31, 2013	18,888,971	18,888,971	'	'	'
Net loss	-196,488	'	'	-196,488	'
Ending balance at Mar. 31, 2014	'	'	'	'	17
Ending balance at Mar. 31, 2014	($962,324)	$1,889	$27,479,913	($28,444,143)	'
Ending balance, shares at Mar. 31, 2014	0	'	'	'	170,001
Ending balance, shares at Mar. 31, 2014	18,888,971	18,888,971	'	'	'

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Operating activities:	'	'
Net loss	($196,488)	($60,545)
Adjustments to reconcile net loss to net cash flows from operating activities:	'	'
Non-cash interest expense	6,666	'
Changes in assets and liabilities:	'	'
Prepaid expense and other current assets	'	-28,922
Accounts payable and other current liabilities	81,317	8,237
Net cash flows from operating activities	-108,505	-81,230
Financing activities:	'	'
Proceeds from related party advances	108,744	'
Net cash flows from financing activities	108,744	'
Net change in cash and cash equivalents	239	-81,230
Cash and cash equivalents at beginning of period	217	857,702
Cash and cash equivalents at end of period	$456	$776,472

Corporate_overview

Corporate overview	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Corporate overview	'
	1. Corporate overview:
	Overview
	The accompanying unaudited condensed financial statements of HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Company”, “HPPI”, “we”, “us” or similar terminology) as successor to Commonwealth Biotechnologies, Inc., a Virginia corporation (“CBI”), have been prepared by the Company without audit. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at March 31, 2014, and for all periods presented, have been made.
	Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to the Securities and Exchange Commission (“SEC”) rules and regulations. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2013, which are included in the Company’s 2013 Annual Report on Form 10-K, filed with the SEC on April 15, 2014 (the “2013 Annual Report”). The accompanying condensed balance sheet at December 31, 2013 has been derived from the audited financial statements at that date, but does not include all information and footnotes required by GAAP for complete financial statements.
	As used herein, the term “Common Stock” means the Company’s common stock, $0.0001 par value per share.
	The results of operations for the three month period ended March 31, 2014 are not necessarily indicative of results that may be expected for any other interim period or for the full fiscal year. Readers of this Quarterly Report are strongly encouraged to review the risk factors relating to the Company which are set forth in the 2013 Annual Report.
	The accompanying financial statements have been prepared on a going concern basis which contemplates the realization of assets and satisfaction of liabilities of the Company in the normal course of business. If the Company is unable to raise required funding to continue to pursue its business plan, it may have to cease operations. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
	Nature of the Business
	The Company’s predecessor, CBI, was a specialized life sciences outsourcing business that offered certain peptide-based discovery chemistry and biology products and services through Mimotopes Pty Limited (“Mimotopes”), a wholly-owned subsidiary of CBI. On January 20, 2011, CBI filed a voluntary petition captioned In re Commonwealth Biotechnologies, Inc., Case No. 11-30381-KRH (the “Chapter 11 case”) in the United States Bankruptcy Court for the Eastern District of Virginia (the “Bankruptcy Court”) seeking relief under the provisions of Chapter 11 of Title 11 of the United States Code (the “Bankruptcy Code”). On April 7, 2011, the Bankruptcy Court approved the private sale of the Mimotopes business unit for a net sales price of $850,000. The sale closed on April 29, 2011.
	On August 12, 2013, in furtherance of CBI’s emergence from bankruptcy as described further below, CBI effected a “short-form” reincorporation merger with HPPI, a newly created and wholly owned Delaware subsidiary of CBI, pursuant to which CBI merged with and into HPPI, with HPPI surviving the merger and with the effect of CBI becoming reincorporated as a Delaware corporation and changing its corporate name. Each outstanding share of CBI was converted into one share of HPPI. HPPI’s Certificate of Incorporation (and thus the Certificate of Incorporation of the surviving company) authorizes the issuance of up to 340,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share.
	As described further below, the Company’s present business is the development of the currently-marketed drug itraconazole (currently approved by the U.S. Food and Drug Administration ((“FDA”)) as an anti-fungal agent) for the treatment of certain cancers.
	Pre-Bankruptcy and Emergence from Bankruptcy
	On January 4, 2013, CBI filed an Amended Plan of Reorganization (the “Plan”) with the Bankruptcy Court. The Plan was approved by a vote of creditors and CBI stockholders on March 21, 2013. CBI received an auction fee of $30,000 from Hedgepath, LLC, a Florida limited liability company (which fee was a binding, irrevocable offer for the purchase of a portion of CBI’s equity interests), in addition to the contribution of Assets as described below. Hedgepath, LLC was the winning bidder for CBI, which is more fully described below. This auction fee was recognized as an increase in additional paid-in capital when the Contribution Agreement (as defined below) became effective.
	On March 29, 2013, the Bankruptcy Court entered an order (the “Confirmation Order”) confirming the Plan pursuant to Chapter 11 of the Bankruptcy Code. Under the terms of the Plan, and pursuant to the Contribution Agreement, Hedgepath, LLC contributed and assigned the Assets (as defined below) to HPPI, as the reorganized debtor, in exchange for the right to receive 90% of fully diluted voting equity in HPPI (in the form of the Series A Preferred Stock, as described below) on the date of issuance, with the prior stockholders of CBI retaining approximately 10% voting equity in HPPI, represented by 100% of the issued and outstanding shares of Common Stock.
	On August 13, 2013, the Company entered into a Contribution Agreement, dated as of August 13, 2013 (the “Contribution Agreement”), by and between the Company and Hedgepath, LLC pursuant to which, and subject to the terms and conditions contained therein, in exchange for the right to receive 170,001 shares of the Company’s newly created Series A Convertible Preferred Stock (the “Series A Preferred Stock”), representing 90% of the fully diluted voting securities of the Company as of the date of issuance (or 170,000,739 shares of Common Stock on an as converted basis), Hedgepath, LLC contributed and/or assigned various assets and contract rights to the Company associated with the going forward business of the Company (collectively, the “Assets”) to the Company as described below.
	(i)	U.S. Provisional Patent Application 61-813,122, “Prostate-Specific Antigen as Biomarker for Hedgehog Pathway Inhibitor Treatment and Prognostic Monitoring of Prostate Cancer” (previously assigned to Hedgepath, LLC by Dr. Frank E. O’Donnell, Jr. and Nicholas J. Virca, as inventors);
	(ii)	U.S. Provisional Patent Application 61-813,823, “Treatment and Prognostic Monitoring of Cancer Using Hedgehog Pathway Inhibitors” (previously assigned to Hedgepath, LLC by Dr. Frank E. O’Donnell, Jr. and Nicholas J. Virca, as inventors);
	(iii)	Assignment of Patents, dated November 1, 2012, by Dr. Frank E. O’Donnell, Jr. in favor of Hedgepath, LLC;
	(iv)	Assignment of Patents, dated November 1, 2012, by Nicholas J. Virca in favor of Hedgepath, LLC;
	(v)	Consulting Agreement, dated and effective as of September 1, 2012, by and between HPPI (as successor to Hedgepath, LLC) and Emmanuel Antonarakis, MD (“Antonarakis”).
	(vi)	Confidentiality and Intellectual Property Assignment Agreement, dated and effective September 1, 2012, between Antonarakis and HPPI (as successor to Hedgepath, LLC), which includes all intellectual property, know-how and other assets assigned to Hedgepath, LLC by Antonarakis under such agreement.
	(vii)	Consulting Agreement, effective as of April 11, 2013, by and between Hedgepath, LLC and Arianne Consulting, Inc. (“Arianne”); and
	(viii)	Confidentiality and Intellectual Property Assignment Agreement, dated and effective April 11, 2013, between Arianne and Hedgepath, LLC , which includes all intellectual property, know-how and other assets assigned to Hedgepath, LLC by Arianne under such agreement.
	The Contribution Agreement was entered into to carry out the purposes and intent of the Plan filed by CBI and confirmed by the Bankruptcy Court in connection with the Chapter 11 case.
	Hedgepath, LLC is a development stage pharmaceutical company. Since its formation in late 2011, Hedgepath, LLC has sought, among other pharmaceutical business opportunities, to acquire technology rights and to conduct activities related to the development of the currently-marketed drug itraconazole (currently FDA approved as an anti-fungal agent) for the treatment of certain cancers (the “Itra Business Opportunity”). Hedgepath, LLC has expended approximately $0.1 million acquiring assets and developing the Itra Business Opportunity, including approximately $82,500 on technical and medical consulting and $15,000 on option fees related to an intellectual property agreement that has since expired.
	In accordance with the Plan, and as a result of the transactions contemplated by the Contribution Agreement, from and after August 13, 2013, HPPI is engaged in pursuing the Itra Business Opportunity. The Assets contributed to the Company by Hedgepath, LLC represent the assets and rights heretofore developed or acquired by Hedgepath, LLC related to the Itra Business Opportunity, and by virtue of the Contribution Agreement, the Company acquired all of Hedgepath, LLC’s right, title and interest in and to the Assets.
	As part of the Contribution Agreement, Hedgepath, LLC, which owned a certain claim against CBI in the amount of $52,500, payable to a third party service provider, contributed such claim to the Company. HPPI has agreed to issue to such service provider a number of restricted shares of its Common Stock to be determined based on the valuation of the shares to be issued to purchasers in connection with HPPI’s planned $5 million offering of securities as described in the Plan. Such shares of Common Stock are to be issued to such service provider within five (5) business days of the final determination of such valuation (as memorialized in the final transaction documentation for such offering).
	Hedgepath, LLC did not contribute any of its liabilities to the Company in connection with the Contribution Agreement, and retained all of its assets other than those related to the Itra Business Opportunity.
	In conjunction with the execution of the Contribution Agreement, the Company has expensed, as in-process research and development cost, approximately $1.0 million during the quarter ended September 30, 2013. The value was calculated by taking 90% of the market capitalization on the date the assets were contributed to reflect the 90% ownership exchanged for the assets contributed by Hedgepath, LLC.
	Post-Bankruptcy Business of HPPI—General
	As a result of the aforementioned transactions, as of August 13, 2013 the Company is a clinical stage biopharmaceutical company that endeavors to discover, develop and commercialize innovative therapeutics for patients with certain cancers. The Company’s preliminary focus will be on the development of therapies for certain cancers, with initial emphasis on skin, prostate and lung cancers in the U.S. market, based upon the use of the currently marketed anti-fungal drug itraconazole. The Company believes that itraconazole could affect the Hedgehog signaling pathway in cells, a major regulator of many fundamental cellular processes, which could, in turn, impact the development and growth of certain cancers.
	Itraconazole is FDA approved for and extensively used to treat fungal infections and has an extensive history of safe and effective use in humans. The Company has developed, optioned and is seeking to acquire and/or license, intellectual property and know-how related to the treatment of cancer patients using itraconazole and has applied for patents to cover the Company’s inventions.

Liquidity_and_managements_plan

Liquidity and management's plans	3 Months Ended
	Mar. 31, 2014
Text Block [Abstract]	'
Liquidity and management's plans	'
	2. Liquidity and management’s plans:
	The Company intends to seek financing for its research and development, commercialization and distribution efforts and its working capital needs primarily through:
		•	public and private financings and, potentially, from strategic transactions;
		•	potential partnerships with other pharmaceutical companies to assist in the supply, manufacturing and distribution of its products for which the Company would expect to receive upfront milestone and royalty payments;
		•	potential licensing and joint venture arrangements with third parties, including other pharmaceutical companies where the Company would receive funding based on out-licensing its product; and
		•	seeking government or private foundation grants which would be awarded to the Company to further develop its current and future anti-cancer therapies.
	However, there can be no assurance that any of these plans will be implemented on commercially reasonable terms, if at all.
	The lack of adequate cash resulting from the predecessor Company’s bankruptcy, the sale of CBI’s principal assets, and the resulting inability to generate cash flow from operations or to raise capital from external sources had a material adverse effect on the Company’s business. Consequently, during 2013 and 2014, the Company’s business has undergone substantial reductions in relation to size, scale and scope of activities. In addition, the Company presently has no material cash resources.
	As a result of the foregoing circumstances, there is substantial doubt about the Company’s ability to continue as a going concern. The Company’s current independent auditors have included a paragraph emphasizing “going concern” uncertainty in their report on the 2013 financial statements. The financial statements included herein do not include any adjustments relating to the recoverability or classification of asset carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.
	The Company had cash and cash equivalents of $456 as of March 31, 2014, and has therefore relied on loans from insiders and affiliates to fund its operations until the Company is able to raise additional capital. Subsequent to March 31, 2014, working capital advances as of the date of this Report from Hedgepath, LLC amounted to approximately $140,000, and have been used for officer and employee salaries, legal and professional fees.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	3. Summary of Significant Accounting Policies:
	Estimates
	The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.
	Revenue Recognition
	The Company currently has no ongoing source of revenues. Any miscellaneous income is recognized when earned by the Company.
	Cash and Cash Equivalents
	The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. At times, the Company may maintain cash balances in excess of Federal Deposit Insurance Corporation insured amounts.
	Research and Development Expenses
	Research and development costs are expensed in the period in which they are incurred and include the expenses paid to third parties who conduct research and development activities on behalf of the Company.
	Accounting for Enterprises in Reorganization
	Financial Accounting Standards Board (“ FASB”) Accounting Standards Codification (“ASC”) Topic 852—Reorganizations (“ASC Topic 852”), which is applicable to companies in Chapter 11, generally does not change the manner in which financial statements are prepared. However, it does require that the financial statements for periods subsequent to the filing of the Chapter 11 petition distinguish transactions and events that are directly associated with the reorganization from the ongoing operations of the business. Revenues, expenses, realized gains and losses, and provisions for losses that can be directly associated with the reorganization and restructuring of the business must be reported separately as reorganization items in the statements of operations beginning in the quarter ending March 31, 2011. The balance sheet must distinguish prepetition liabilities subject to compromise from both those prepetition liabilities that are not subject to compromise and from post-petition liabilities. Liabilities that may be affected by a plan of reorganization must be reported at the amounts expected to be allowed by the Bankruptcy Court, even if they may be settled for lesser amounts. In addition, cash flows from reorganization items must be disclosed separately in the statement of cash flows. The Company became subject to ASC Topic 852 effective on January 20, 2011, and has segregated those items as outlined above for all reporting periods after such date. The Company officially emerged from bankruptcy on April 17, 2013, followed by the reincorporation merger, which satisfied the final condition to effectiveness of the Plan as detailed in Note 1.
	Income taxes
	Deferred tax assets and liabilities are recognized for future tax consequences attributed to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases and are measured using enacted tax rates that are expected to apply to the differences in the periods that they are expected to reverse. Management has evaluated the guidance relating to accounting for uncertainty in income taxes and has determined that the Company had no uncertain income tax positions that could have a significant effect on the consolidated financial statements for the three months ended March 31, 2014 or 2013.

Supply_and_License_Agreement

Supply and License Agreement	3 Months Ended
	Mar. 31, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Supply and License Agreement	'
	4. Supply and License Agreement:
	On September 3, 2013, the Company entered into an exclusive Supply and License Agreement (the “Supply and License Agreement”) with Mayne Pharma International Pty Ltd., a company incorporated in Australia (“Mayne Pharma”), pursuant to which Mayne Pharma agreed to: (i) supply the Company with its patented formulation of the drug itraconazole, known as SUBA™-Itraconazole, in a particular dose formulation (the “Product”) for the treatment of human patients with cancer via oral administration (the “Field”) (with the initial areas of investigation being prostate, lung and skin cancer) in the United States (the “Territory”), (ii) provide the Company with an exclusive license to use and develop the intellectual property related to the Product in the Field and in the Territory and (iii) participate in a joint development committee with the Company (“JDC”) to clinically develop the Product in the Field and in the Territory. The Company will pursue the development of the Product for treatment of a variety of cancers with a focus on clinical development, seeking regulatory approvals and, if regulatory approval is obtained, marketing in the United States.
	Subject to earlier termination if certain conditions are not met, the term of the Supply and License Agreement shall last until the later of: (i) 10 years from the target launch date of the Product for the treatment of human patients with cancer via oral administration or (ii) the date on which all issued patents of Mayne Pharma or any of its affiliates referred to in the Supply and License Agreement have lapsed or expired.
	On December 17, 2013, the Company entered into Amendment No. 1 to the Supply and License Agreement (the “Amended Supply and License Agreement”) with Mayne Pharma to extend the date by which the conditions must be met to February 28, 2014.
	As provided for in the Agreement, as amended, Mayne Pharma could have terminated the Agreement since certain conditions were not met by February 28, 2014. On March 5, 2014, the Company entered into Amendment No. 2 to the Supply and License Agreement (the “Amended Supply and License Agreement”) with Mayne Pharma which extended the date by which the conditions must be met to March 31, 2014.
	Mayne Pharma had the right to terminate the Supply and License Agreement, as amended, if certain conditions were not met by March 31, 2014. That date was extended to April 25, 2014 by mutual agreement. The Company is continuing efforts to meet those conditions, and the Supply and License Agreement remains subject to termination. No transactions under the original or amended Supply and License Agreement have transpired to date.

Notes_Payable

Notes Payable	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Notes Payable	'
	5. Notes Payable:
	On August 1, 2013, the Company formalized amounts due to two former employees and a former director of CBI by issuing three non-interest bearing promissory notes. The two employee notes totaling approximately $62,000 were due on November 1, 2013. Interest will accrue at 18% per annum on any unpaid principal upon default. As of the date of this report, the Company is in default on the aforementioned notes. The Company is now accruing interest in accordance with the specified terms.
	On January 31, 2014, the Company extended the two former employee notes. The amendments include additional principal of approximately $9,000 were due on March 31, 2014. As of the date of this report, the Company is in default on the aforementioned notes. The Company is now accruing interest in accordance with the specified terms.
	The former director note of approximately $6,000 is due the later of five days following the date on which the Company has raised $1 million, or November 1, 2013. Default interest accrues at a rate of 5% per annum. As of the date of this report, the Company is in default on the aforementioned note. The Company is now accruing interest in accordance with the specified terms. Both the employee and director note amounts, including accrued interest, are included in notes payable, in the accompanying balance sheet as of March 31, 2014.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Stockholders' Equity	'
	6. Stockholders’ Equity:
	Employee Stock Plans
	A 2002 Stock Incentive Plan was adopted by the Board of Directors and approved by the shareholders of CBI. However, all options were canceled on July 16, 2013, which was 90 days subsequent to the effective date of the emergence from bankruptcy.
	A 2007 Stock Incentive Plan was adopted by the Board of Directors and approved by the shareholders of CBI. However, all options were canceled on July 16, 2013, which was 90 days subsequent to the effective date of the emergence from bankruptcy.
	A 2009 Stock Incentive Plan was adopted by the Board of Directors and approved by the shareholders of CBI. There are no options outstanding under this plan.
	Going forward, incentive awards may be in the form of stock options, restricted stock, restricted stock units and performance and other awards. In the case of incentive stock options, the exercise price will not be less than 100% of the fair market value of shares covered at the time of the grant, or 110% for incentive stock options granted to persons who own more than 10% of the Company’s voting stock. Options granted will generally vest over a three-year period from the date of grant and will be exercisable for ten years, except that the term may not exceed five years for incentive stock options granted to persons who own more than 10% of the Company’s outstanding common stock.
	Stock-based compensation expense will be determined based on the fair value of the stock-based awards and recognized over the vesting period. No stock-based compensation expense related to employee stock options was recognized for the three months ended March 31, 2014 or 2013. As of March 31, 2014 there was no unamortized stock-based compensation cost related to non-vested stock awards, as all such instruments were canceled upon emergence from bankruptcy. During the three months ended March 31, 2014, no stock options were granted, exercised or forfeited.
	Issuance of Restricted Stock
	In April 2013, restricted shares were issued to CBI’s CEO, one CBI board member and one former CBI officer for a portion of their approved claims. The number of shares issued, which totaled 3,328,467, was determined by using a per share price equal to the average of the 30 day closing price of Common Stock and was valued at $152,000.
	Warrants
	In connection with a 2007 private placement financing, CBI issued Class A warrants to purchase 975,000 shares of common stock at an exercise price of $2.85 per share that had an expiration date of May 2013. On March 20, 2013, CBI filed a motion to cancel all outstanding warrants under the terms of the Bankruptcy Code. This motion was approved and entered by the Bankruptcy Court in April 2013. As such, there are no warrants outstanding at March 31, 2014.

Related_party_transactions

Related party transactions	3 Months Ended
	Mar. 31, 2014
Related Party Transactions [Abstract]	'
Related party transactions	'
	7. Related party transactions:
	As part of the short-form reincorporation merger with HPPI, certain expenses have been incurred for officer salary, travel, legal and patent expense. These expenses, totaling $474,874, were paid by Hedgepath, LLC on behalf of the newly formed HPPI and are included in due to related party in the accompanying balance sheet as of March 31, 2014. Subsequent to March 31, 3014, working capital advances as of the date of this report from Hedgepath, LLC approximate $140,000, and have been used for officer and employee salaries, legal and professional fees.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Estimates	'
	Estimates
	The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.
Revenue Recognition	'
	Revenue Recognition
	The Company currently has no ongoing source of revenues. Any miscellaneous income is recognized when earned by the Company.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. At times, the Company may maintain cash balances in excess of Federal Deposit Insurance Corporation insured amounts.
Research and Development Expenses	'
	Research and Development Expenses
	Research and development costs are expensed in the period in which they are incurred and include the expenses paid to third parties who conduct research and development activities on behalf of the Company.
Accounting for Enterprises in Reorganization	'
	Accounting for Enterprises in Reorganization
	Financial Accounting Standards Board (“ FASB”) Accounting Standards Codification (“ASC”) Topic 852—Reorganizations (“ASC Topic 852”), which is applicable to companies in Chapter 11, generally does not change the manner in which financial statements are prepared. However, it does require that the financial statements for periods subsequent to the filing of the Chapter 11 petition distinguish transactions and events that are directly associated with the reorganization from the ongoing operations of the business. Revenues, expenses, realized gains and losses, and provisions for losses that can be directly associated with the reorganization and restructuring of the business must be reported separately as reorganization items in the statements of operations beginning in the quarter ending March 31, 2011. The balance sheet must distinguish prepetition liabilities subject to compromise from both those prepetition liabilities that are not subject to compromise and from post-petition liabilities. Liabilities that may be affected by a plan of reorganization must be reported at the amounts expected to be allowed by the Bankruptcy Court, even if they may be settled for lesser amounts. In addition, cash flows from reorganization items must be disclosed separately in the statement of cash flows. The Company became subject to ASC Topic 852 effective on January 20, 2011, and has segregated those items as outlined above for all reporting periods after such date. The Company officially emerged from bankruptcy on April 17, 2013, followed by the reincorporation merger, which satisfied the final condition to effectiveness of the Plan as detailed in Note 1.
Income taxes	'
	Income taxes
	Deferred tax assets and liabilities are recognized for future tax consequences attributed to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases and are measured using enacted tax rates that are expected to apply to the differences in the periods that they are expected to reverse. Management has evaluated the guidance relating to accounting for uncertainty in income taxes and has determined that the Company had no uncertain income tax positions that could have a significant effect on the consolidated financial statements for the three months ended March 31, 2014 or 2013.

Corporate_Overview_Additional_

Corporate Overview - Additional Information (Detail) (USD $)

0 Months Ended

0 Months Ended

3 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

Mar. 29, 2013

Mar. 31, 2014

Dec. 31, 2013

Jan. 04, 2013

Mar. 31, 2014

Sep. 30, 2013

Aug. 13, 2013

Mar. 29, 2013

Mar. 31, 2014

Aug. 12, 2013

Mar. 31, 2014

Aug. 13, 2013

Aug. 12, 2013

Aug. 12, 2013

Aug. 12, 2013

Aug. 12, 2013

Apr. 07, 2011

Mar. 31, 2014

Hedgepath LLC [Member]

Contribution Agreement [Member]

Contribution Agreement [Member]

Contribution Agreement [Member]

Contribution Agreement [Member]

Contribution Agreement [Member]

Commonwealth Biotechnologies, Inc. [Member]

Commonwealth Biotechnologies, Inc. [Member]

Series A Preferred Stock [Member]

Common Stock [Member]

Common Stock [Member]

Preferred Stock [Member]

Preferred Stock [Member]

Mimotopes Pty Limited [Member]

Mimotopes Pty Limited [Member]

Hedgepath LLC [Member]

Contribution Agreement [Member]

Contribution Agreement [Member]

Maximum [Member]

Maximum [Member]

Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, par value

'

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net selling price of CBI Mimotopes business unit

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$850,000

'

Closing date of sale of business unit

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

29-Apr-11

Conversion ratio

'

'

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

'

Issuance of HPPI's shares to CBI's shareholders, stock

'

'

'

'

'

'

'

'

'

'

'

'

'

340,000,000

'

10,000,000

'

'

Par value assigned stock after merger

'

'

'

'

'

'

'

'

'

'

'

'

$0.00

'

$0.00

'

'

'

Auction fees paid by Hedgepath, LLC to CBI

'

'

'

30,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of voting rights retained by the prior stockholders of CBI in HPPI

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

Total percentage of issued and outstanding shares of HPPI common stock

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ownership interest exchanged for the assets contributed

90.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of convertible preferred stock representing diluted voting securities

'

'

'

'

'

'

'

'

'

'

'

90.00%

'

'

'

'

'

'

Number of shares in exchange for right to receive

'

'

'

'

'

'

'

'

'

'

'

170,001

'

'

'

'

'

'

Shares of common stock under contribution agreement after conversion of preferred stock

'

18,888,971

18,888,971

'

'

'

170,000,739

'

'

'

'

'

'

'

'

'

'

'

Expenses incurred for acquiring assets and developing ITRA business opportunity

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

Expenses incurred on technical and medical consulting

'

'

'

'

'

'

'

'

82,500

'

'

'

'

'

'

'

'

'

Expenses incurred on option fees

'

'

'

'

'

'

'

'

15,000

'

'

'

'

'

'

'

'

'

Hedgepath, LLC's claim against CBI

'

'

'

'

'

'

'

'

'

'

52,500

'

'

'

'

'

'

'

Value of securities planned to offer as a part of contribution agreement

'

10,000

10,000

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum number of days after determination of valuation within which the securities should be offered

'

'

'

'

'5 days

'

'

'

'

'

'

'

'

'

'

'

'

'

Research and development cost to be expensed for the execution of contribution agreement

'

'

'

'

'

$1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of market capitalization considered for calculating the Research and development cost

'

'

'

'

90.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Recovered_Sheet1

Liquidity and Management's Plans - Additional Information (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Jan. 04, 2013
Reorganizations [Abstract]	'	'	'	'
Cash and cash equivalents	$456	$217	$776,472	$857,702
Working capital advances from Hedgepath, LLC	$140,000	'	'	'

Supply_and_License_Agreement_A

Supply and License Agreement - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Supply and License Agreement from the date of the first commercial sale of the product	'10 years

Notes_Payable_Additional_Infor

Notes Payable- Additional Information (Detail) (Promissory Notes [Member], USD $)	0 Months Ended
	Aug. 01, 2013	Jan. 31, 2014
Debt Instrument [Line Items]	'	'
Number of non-interest promissory notes	3	'
Number of employees for notes	2	'
Promissory note due period	'5 days	'
Fund amount to be raise under condition one	$1,000,000	'
Expected maturity date under condition two	1-Nov-13	'
Employees [Member]	'	'
Debt Instrument [Line Items]	'	'
Notes due	62,000	9,000
Interest to be paid on default of promissory note	18.00%	'
Board Member [Member]	'	'
Debt Instrument [Line Items]	'	'
Notes due	$6,000	'
Interest to be paid on default of promissory note	5.00%	'

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended	1 Months Ended		0 Months Ended
	Apr. 30, 2013	Mar. 31, 2014	Apr. 30, 2013	Apr. 30, 2013	Jul. 16, 2013	Jul. 16, 2013	Mar. 31, 2014
	Office		Commonwealth Biotechnologies, Inc. [Member]	CEO [Member]	2002 Stock Incentive Plan [Member]	2007 Stock Incentive Plan [Member]	2009 Stock Incentive Plan [Member]
			Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Period of cancellation of options	'	'	'	'	'90 days	'90 days	'
Options cancellation date	'	'	'	'	16-Jul-13	16-Jul-13	'
Option outstanding under 2009 stock incentive plan	'	'	'	'	'	'	0
Minimum exercise price of the fair market value of shares	'	100.00%	'	'	'	'	'
Minimum exercise price for incentive stock options granted to persons who own more than 10% of the company's voting stock	'	110.00%	'	'	'	'	'
Minimum percentage of the company's voting stock for grant of incentive stock options	'	10.00%	'	'	'	'	'
Options granted vesting period	'	'3 years	'	'	'	'	'
Options exercisable period	'	'10 years	'	'	'	'	'
Maximum period for grant of incentive stock options	'	'5 years	'	'	'	'	'
Stock-based compensation expense related to employee stock options	'	$0	'	'	'	'	'
Unamortized stock-based compensation cost related to non-vested stock awards	'	0	'	'	'	'	'
Stock options were granted	'	0	'	'	'	'	'
Stock options were exercised or forfeited	'	0	'	'	'	'	'
Period of average closing price of common stock	'	'	'30 days	'	'	'	'
Number of board member to whom restricted shares were issued	'	'	1	'	'	'	'
Number of former officer to whom restricted shares were issued	1	'	'	'	'	'	'
Restricted stock share issued	'	'	'	3,328,467	'	'	'
Market value of restricted stock	'	'	'	$152,000	'	'	'
Number of security called by warrant	'	975,000	'	'	'	'	'
Class of warrant exercise price	'	2.85	'	'	'	'	'
Warrants outstanding	'	0	'	'	'	'	'

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Related Party Transaction [Line Items]	'	'
Due to related party	$474,874	$366,130
Working capital advances	140,000	'
Hedgepath LLC [Member]	'	'
Related Party Transaction [Line Items]	'	'
Due to related party	474,874	'
Working capital advances	$140,000	'